References
- Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate-specific antigen. Invest Urol 1979; 17: 159–63
- Allard WJ, Cheli CD, Morris DL, Goldblatt J, Pierre Y, Kish L, et al. Multicenter evaluation of the performance and clinical utility in longitudinal monitoring of the Bayer Immuno 1 complexed PSA assay. Int J Biol Markers 1999; 14: 73–83
- Port FK, Ragheb NE, Schwartz AG, Hawthorne VM. Neoplasms in dialysis patients: a population-based study. Am J Kidney Dis 1989; 14: 119–23
- Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354: 93–9
- Khairullah QT, Pamatmat SD, Chatha M, Provenzano R, Telang D, Temple M. Early detection of prostate cancer in the ESRD population. Clin Nephrol 2002; 61: 308–15
- Bruun L, Bjork T, Lilja H, Becker C, Gustafsson O, Christensson A. Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment. Nephrol Dial Transplant 2003; 18: 598–603
- Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997; 277: 1452–5
- Okihara K, Fritsche HA, Ayala A, Johnston DA, Allard WE, Babaian RJ. Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between: 2.5 and 4.0 ng./ml. J Urol 2001; 165: 1930–6
- Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of percentage of free prostate specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. A prospective multicenter clinical trial. JAMA 1998; 279: 1542–7
- Kiliç S, Yalçinkaya S, Güntekin E, Kukul E, Deger N, Sevuk M. Determination of the site of metabolism of total, free and complexed prostate specific antigen. Urology 1998; 52: 470–3
- Monath JR, Burkart JM, Freedman BI, Pittaway DE, Russell GB, Assimos DG. Effects of hemodialysis on prostate-specific antigen. Urology 1993; 42: 398–400
- Sasagawa I, Kubota Y, Hayami S, Adachi M, Nakada T, Miura H, et al. Serum levels of total and free prostate specific antigen in men on hemodialysis. J Urol 1998; 160: 83–5
- Djavan B, Shariad S, Ghawidel K, Marberger KG, Remzi M, Kovarik J, et al. Impact of chronic dialysis on serum PSA, free PSA, and free/total PSA ratio: is prostate cancer detection compromised in patients receiving long-term dialysis?. Urology 1999; 53: 1169–74
- Wolff JM, Ting O, Borchers H, Rohde D, Jakse G. Serum levels of prostate specific antigen in men on hemodialysis. Anticancer Res 2000; 20: 5191–4
- Danisman A, Kilic S, Kukul E, Yakupoglu G, Guntekin E, Baykara M, et al. Do renal failure and hemodialysis have any effect on the elimination of free and total prostate-specific antigen?. Eur Urol 2000; 37: 579–81
- Tzanakis I, Kazoulis S, Girousis N, Kagia S, Spandidakis V, Karefillakis N, et al. Prostate-specific antigen in hemodialysis patients and the influence of dialysis in its levels. Nephron 2002; 90: 230–3
- Leinonen J, Zhang WM, Stenman UH. Complex formation between PSA isoenzymes and protease inhibitors. J Urol 1996; 155: 1099–103